Pre-Open Stock Movers 09/01: (ABVC) (PLAN) (BLCM) Higher; (LCID) (NIO) (ASND) Lower (more...)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to Pre-Open Stock Movers 09/01: (ABVC) (PLAN) (BLCM) Higher; (LCID) (NIO) (ASND) Lower (more...)

PVH Corp (PVH) PT Raised to $136 at BofA Securities

September 2, 2021 7:55 AM EDT

BofA Securities analyst Lorraine Hutchinson raised the price target on PVH Corp (NYSE: PVH) to $136.00 (from $125.00) while maintaining a Buy rating.

... More

Ascendis Pharma (ASND) Prices 2.5M ADS Offering at $160/sh

September 2, 2021 5:23 AM EDT

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new treatments that make a meaningful difference in patients lives, today announced the pricing of its underwritten public offering of 2,500,000 American Depositary Shares (ADSs), each of which represents one ordinary share of Ascendis, at a price to the public of $160.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about September 7, 2021 subject to customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to... More

Takeda Pharmaceutical Co. Ltd. (TAK) Phase 3 PANTHER (Pevonedistat-3001) Trial Did Not Achieve Primary Endpoint

September 1, 2021 4:32 PM EDT

Takeda Pharmaceutical Company Limited (NYSE: TAK) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the... More

Campbell Soup (CPB) PT Lowered to $44 at Stifel

September 1, 2021 3:12 PM EDT

Stifel analyst Christopher Growe lowered the price target on Campbell Soup (NYSE: CPB) to $44.00 (from $48.00) while maintaining a Hold rating following earnings.

The analyst commented, "Campbell Soup reported 4Q21 EPS of $0.55, representing a 13% decline and standing $0.07 ahead of our estimate. The sales and profit... More

Anaplan Inc. (PLAN) PT Raised to $101 at Monness, Crespi, Hardt

September 1, 2021 10:57 AM EDT

Monness, Crespi, Hardt analyst Brian White raised the price target on Anaplan Inc. (NYSE: PLAN) to $101.00 (from $90.00) while maintaining a Buy rating following earnings.

The analyst commented, "Anaplan delivered exceptional 2Q:FY22 results, while issuing strong 3Q:FY22 guidance, and raising... More